The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML 15 trial

AK Burnett, WJ Kell, AH Goldstone, D Milligan, Keith Wheatley, A Hunter, AG Prentice, NH Russell, B Gibson, Robert Hills

Research output: Contribution to conference (unpublished)Abstract

Original languageEnglish
Publication statusPublished - 1 Jan 2006
EventBlood, 48th Annual Meeting -
Duration: 1 Jan 2006 → …


ConferenceBlood, 48th Annual Meeting
Period1/01/06 → …

Cite this